Kris Jacobs

1.0k total citations
17 papers, 380 citations indexed

About

Kris Jacobs is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Molecular Biology. According to data from OpenAlex, Kris Jacobs has authored 17 papers receiving a total of 380 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 9 papers in Public Health, Environmental and Occupational Health and 6 papers in Molecular Biology. Recurrent topics in Kris Jacobs's work include Acute Lymphoblastic Leukemia research (9 papers), Chronic Myeloid Leukemia Treatments (9 papers) and Acute Myeloid Leukemia Research (8 papers). Kris Jacobs is often cited by papers focused on Acute Lymphoblastic Leukemia research (9 papers), Chronic Myeloid Leukemia Treatments (9 papers) and Acute Myeloid Leukemia Research (8 papers). Kris Jacobs collaborates with scholars based in Belgium, Australia and United States. Kris Jacobs's co-authors include Jan Cools, Sofie Demeyer, Olga Gielen, Charles E. de Bock, Nicole Mentens, Ellen Geerdens, Sandrine Degryse, Thomas Tousseyn, Marlies Vanden Bempt and Delphine Verbeke and has published in prestigious journals such as Nature Communications, Blood and PLoS ONE.

In The Last Decade

Kris Jacobs

17 papers receiving 380 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kris Jacobs Belgium 12 135 127 117 115 93 17 380
Sandrine Degryse Belgium 8 156 1.2× 211 1.7× 141 1.2× 202 1.8× 95 1.0× 11 485
Stefan Koehrer United States 9 125 0.9× 64 0.5× 83 0.7× 41 0.4× 69 0.7× 14 287
Pasquale L. Fedele Australia 11 118 0.9× 125 1.0× 100 0.9× 33 0.3× 127 1.4× 24 388
Josephine L. Klitgaard United States 7 178 1.3× 108 0.9× 133 1.1× 14 0.1× 97 1.0× 11 426
Patrícia Yoshioka Jotta Brazil 6 333 2.5× 161 1.3× 96 0.8× 168 1.5× 43 0.5× 11 488
Neil Came Australia 8 106 0.8× 186 1.5× 74 0.6× 32 0.3× 106 1.1× 17 308
Sandra Heesch Germany 15 382 2.8× 368 2.9× 104 0.9× 376 3.3× 74 0.8× 21 777
Ellen Wollmer Germany 7 181 1.3× 250 2.0× 115 1.0× 49 0.4× 23 0.2× 12 455
Jonathan A. Schumacher United States 11 137 1.0× 89 0.7× 62 0.5× 17 0.1× 122 1.3× 25 374
Tatjana Walther Germany 6 171 1.3× 41 0.3× 79 0.7× 24 0.2× 54 0.6× 7 317

Countries citing papers authored by Kris Jacobs

Since Specialization
Citations

This map shows the geographic impact of Kris Jacobs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kris Jacobs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kris Jacobs more than expected).

Fields of papers citing papers by Kris Jacobs

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kris Jacobs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kris Jacobs. The network helps show where Kris Jacobs may publish in the future.

Co-authorship network of co-authors of Kris Jacobs

This figure shows the co-authorship network connecting the top 25 collaborators of Kris Jacobs. A scholar is included among the top collaborators of Kris Jacobs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kris Jacobs. Kris Jacobs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Demeyer, Sofie, Nicole Mentens, Kris Jacobs, et al.. (2025). TLE4 is a repressor of the oncogenic activity of TLX3 in T-cell acute lymphoblastic leukemia. Leukemia. 39(3). 568–576. 1 indexed citations
2.
Bempt, Marlies Vanden, Koen Debackere, Sofie Demeyer, et al.. (2022). Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T-cell lymphoma. Blood. 140(23). 2463–2476. 12 indexed citations
3.
Debackere, Koen, Lukas Marcelis, Sofie Demeyer, et al.. (2021). Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specified. Nature Communications. 12(1). 3705–3705. 18 indexed citations
4.
Prieto, Cristina, Olga Gielen, Kris Jacobs, et al.. (2021). PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia. Journal of Hematology & Oncology. 14(1). 97–97. 12 indexed citations
5.
Lodewijckx, Inge, Nicole Mentens, Kris Jacobs, & Jan Cools. (2021). Oncogenic Cooperation Between IL7R-JAK-STAT Pathway Mutations. HemaSphere. 5(9). e637–e637. 4 indexed citations
6.
Verbeke, Delphine, Sofie Demeyer, Cristina Prieto, et al.. (2020). The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia. Clinical Cancer Research. 26(21). 5747–5758. 21 indexed citations
7.
Broux, Michaël, Cristina Prieto, Sofie Demeyer, et al.. (2019). Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia. Blood. 134(16). 1323–1336. 33 indexed citations
8.
Verbeke, Delphine, Olga Gielen, Kris Jacobs, et al.. (2019). Ruxolitinib Synergizes With Dexamethasone for the Treatment of T-cell Acute Lymphoblastic Leukemia. HemaSphere. 3(6). e310–e310. 16 indexed citations
9.
Jacobs, Kris, et al.. (2019). JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 Inhibitors. HemaSphere. 3(6). e313–e313. 12 indexed citations
10.
Bempt, Marlies Vanden, José Luis Ferreiro, Nicole Mentens, et al.. (2017). Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene. Haematologica. 102(9). 1605–1616. 26 indexed citations
11.
Degryse, Sandrine, Charles E. de Bock, Sofie Demeyer, et al.. (2017). Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia. 32(3). 788–800. 64 indexed citations
12.
Degryse, Sandrine, Simon Bornschein, Charles E. de Bock, et al.. (2017). Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL. Blood. 131(4). 421–425. 30 indexed citations
13.
Wandinger, Sebastian K., Idoya Lahortiga, Kris Jacobs, et al.. (2016). Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling. PLoS ONE. 11(1). e0146100–e0146100. 13 indexed citations
14.
Versele, Matthias, Burkhard Haefner, Berthold Wroblowski, et al.. (2016). Abstract 4800: Covalent Flt3-Cys828 inhibition represents a novel therapeutic approach for the treatment of Flt3-ITD and Flt3-D835 mutant acute myeloid leukemia. Cancer Research. 76(14_Supplement). 4800–4800. 2 indexed citations
15.
Degryse, Sandrine, Charles E. de Bock, Luk Cox, et al.. (2014). JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 124(20). 3092–3100. 109 indexed citations
16.
Degryse, Sandrine, Charles E. de Bock, Carmen Vicente, et al.. (2014). JAK3 Mutants Transform Hematopoietic Cells through JAK1 Activation Causing T-Cell Acute Lymphoblastic Leukemia in a Bone Marrow Transplant Mouse Model. Blood. 124(21). 361–361. 1 indexed citations
17.
Klaassen, Hugo, Idoya Lahortiga, Kris Jacobs, et al.. (2013). Identification of novel FLT3 kinase inhibitors. European Journal of Medicinal Chemistry. 63. 713–721. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sandrine Degryse Breakdown of academic impact, for papers by Stefan Koehrer Breakdown of academic impact, for papers by Pasquale L. Fedele Breakdown of academic impact, for papers by Josephine L. Klitgaard Breakdown of academic impact, for papers by Patrícia Yoshioka Jotta Breakdown of academic impact, for papers by Neil Came Breakdown of academic impact, for papers by Sandra Heesch Breakdown of academic impact, for papers by Ellen Wollmer Breakdown of academic impact, for papers by Jonathan A. Schumacher Breakdown of academic impact, for papers by Tatjana Walther
Rankless by CCL
2026